Status:
COMPLETED
Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis
Lead Sponsor:
AstraZeneca
Conditions:
Hyperkalemia
Hemodialysis
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to evaluate the prevalence and recurrence of Hyperkalaemia (HK) in Chinese HD patients and to understand the treatment pattern of HK in China.
Detailed Description
This is a prospective, cohort study. This study will include approximate 600 End Stage Renal Disease (ESRD) patients receiving Haemodialysis (HD) treatment twice a week or thrice a week. The assessme...
Eligibility Criteria
Inclusion
- Patient aged ≥ 18 years at the time of signing the informed consent.
- Patients with ESRD and on haemodialysis (HD)
- The HD treatment frequency is ≥2 sessions per week
- Capable of giving signed informed consent
Exclusion
- Acute kidney injury
- Expected to receive renal transplantation within 6 months
- Intracranial haemorrhage or elevated intracranial pressure within one month before enrolment
- Shock that cannot be corrected by drugs within one month before enrolment
- Failure to establish vascular access
- Has been receiving peritoneal dialysis
- Not suitable for this study judged by investigators
Key Trial Info
Start Date :
May 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04799067
Start Date
May 17 2021
End Date
July 18 2022
Last Update
July 6 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, Beijing Municipality, China
2
Research Site
Guangzhou, Guangdong, China
3
Research Site
Shenzhen, Guangdong, China
4
Research Site
Shijiazhuang, Hebei, China